Skip to content
Clinical Trials – home

University Of Debrecen

Verified siteinfo

Hungary Nagyerdei Korut 98, 4032 Debrecen, Hungary

  • 182 trials recruiting
  • Dermatitis atopic · Psoriasis · Obesity
  • Adults and children

About Specializations

University Of Debrecen in Debrecen, Hungary specialises in clinical trials of conditions such as Dermatitis atopic, Psoriasis, Obesity, Sjogren's syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of cancer. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies and personalized medicine.

  • Renal Cell Carcinoma
  • Colorectal Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Lung Cancer
  • Prostate Cancer

Through its research, the center is advancing the understanding of cancer biology and developing novel therapeutic strategies that are transforming the landscape of cancer treatment.

Dermatology

Specializing in dermatology, the center is pioneering research in skin-related conditions, focusing on both common and rare disorders. The research aims to enhance treatment efficacy and patient quality of life.

  • Alopecia Areata
  • Atopic Dermatitis
  • Psoriasis
  • Hidradenitis Suppurativa
  • Pyoderma Gangrenosum

The center's work in dermatology is contributing to the development of new therapies and improving the management of chronic skin conditions.

Gastroenterology

In the field of gastroenterology, the center is conducting groundbreaking research to address complex digestive disorders. The focus is on innovative treatments that offer hope to patients with challenging conditions.

  • Crohn's Disease
  • Ulcerative Colitis
  • Hepatic Encephalopathy
  • Liver Cirrhosis
  • Endometriosis

By advancing research in gastroenterology, the center is enhancing the understanding of these conditions and developing new therapeutic approaches.

Ophthalmology

The center is a leader in ophthalmology research, focusing on eye diseases that affect vision and quality of life. The research is aimed at developing treatments that preserve and restore sight.

  • Macular Edema
  • Diabetic Macular Edema

Through its innovative research, the center is making significant strides in the treatment of eye conditions, offering new hope to patients worldwide.

Cardiology and Metabolic Disorders

In the realm of cardiology and metabolic disorders, the center is exploring new frontiers in the treatment of heart and metabolic diseases. The research is focused on improving patient outcomes through advanced therapies.

  • Hypertriglyceridemia
  • Obesity
  • Osteoarthritis

The center's research is paving the way for new treatments that address the root causes of these conditions, improving patient health and quality of life.

Hematology

Specializing in hematology, the center is advancing research in blood disorders, focusing on innovative treatments that improve patient care and outcomes.

  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Chronic Lymphocytic Leukemia
  • Essential Thrombocythaemia

The center's work in hematology is contributing to the development of new therapies that are transforming the treatment landscape for blood disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Nagyerdei Korut 984032 DebrecenHungary
Recruiting now
182 trials
Conditions studied
281
Partner status
Verified site

More sites in DebrecenHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

529 clinical trials

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.